CoChat

The Trem2 R47H variant confers loss-of-function-like phenotypes in Alzheimer's disease

Open access

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Abstract

BACKGROUND: The R47H variant of Triggering Receptor Expressed on Myeloid cells 2 (TREM2) confers greatly increased risk for Alzheimer's disease (AD), reflective of a central role for myeloid cells in neurodegeneration. Understanding how this variant confers AD risk promises to provide important insights into how myeloid cells contribute to AD pathogenesis and progression. METHODS: In order to investigate this mechanism, CRISPR/Cas9 was used to generate a mouse model of AD harboring one copy of the single nucleotide polymorphism (SNP) encoding the R47H variant in murine Trem2. TREM2 expression, myeloid cell responses to amyloid deposition, plaque burden, and neuritic dystrophy were assessed at 4 months of age. RESULTS: AD mice heterozygous for the Trem2 R47H allele exhibited reduced total Trem2 mRNA expression, reduced TREM2 expression around plaques, and reduced association of myeloid cells with plaques. These results were comparable to AD mice lacking one copy of Trem2. AD mice heterozygous for the Trem2 R47H allele also showed reduced myeloid cell responses to amyloid deposition, including a reduction in proliferation and a reduction in CD45 expression around plaques. Expression of the Trem2 R47H variant also reduced dense core plaque number but increased plaque-associated neuritic dystrophy. CONCLUSIONS: These data suggest that the AD-associated TREM2 R47H variant increases risk for AD by conferring a loss of TREM2 function and enhancing neuritic dystrophy around plaques.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13024-018-0262-8

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 TREM2 expression is significantly reduced in AD mice expressing the Trem2 R47H variant. a Immunohistochemistry was used to identify myeloid cells (IBA1, green), plaques (6E10, blue), and TREM2 (red). b Trem2 RNA levels were assessed in cortical and hippocampal lysates from APPPS1–21;Trem2+/+ (n = 14), APPPS1–21;Trem2+/− (n = 13), and APPPS1–21;Trem2+/R47H (n = 10) mice. Data are presented as fold change normalized gene expression relative to Trem2+/+ mice (n = 9). c Images were quantified to assess TREM2-immunoreactive area and (d) the ratio of TREM2 to IBA1 immunoreactive area around plaques (n = 10–13 mice / genotype). Data are presented as mean ± SEM. *p < 0.05; ***p < 0.001; ns - not significant. Representative images are from the cortex
Fig. 1 TREM2 expression is significantly reduced in AD mice expressing the Trem2 R47H variant. a Immunohistochemistry was used to identify myeloid cells (IBA1, green), plaques (6E10, blue), and TREM2 (red). b Trem2 RNA levels were assessed in cortical and hippocampal lysates from APPPS1–21;Trem2+/+ (n = 14), APPPS1–21;Trem2+/− (n = 13), and APPPS1–21;Trem2+/R47H (n = 10) mice. Data are presented as fold change normalized gene expression relative to Trem2+/+ mice (n = 9). c Images were quantified to assess TREM2-immunoreactive area and (d) the ratio of TREM2 to IBA1 immunoreactive area around plaques (n = 10–13 mice / genotype). Data are presented as mean ± SEM. *p < 0.05; ***p < 0.001; ns - not significant. Representative images are from the cortexCC BY · PubMed Central
Fig. 2 Plaque-associated myeloid cells are reduced in mice expressing the Trem2 R47H variant. a Immunohistochemistry was used to quantify the number of myeloid cells (IBA1, green) around plaques (6E10, blue). b Cells expressing high levels of CD45 (magenta) around plaques (6E10, blue) were identified by immunohistochemistry and the percent CD45-positive area per plaque was quantified. c Proliferating (Ki67-positive, red) myeloid cells (IBA1-positive, green) were quantified across the entire cortex and hippocampus from one medial and one lateral section. Data from APPPS1–21; Trem2+/+ (n = 8), APPPS1–21;Trem2+/− (n = 8), and APPPS1–21;Trem2+/R47H (n = 10) mice are represented as mean ± SEM. *p < 0.05; ** p < 0.01; ***p < 0.001; ns - not significant. Representative images are from the cortex
Fig. 2 Plaque-associated myeloid cells are reduced in mice expressing the Trem2 R47H variant. a Immunohistochemistry was used to quantify the number of myeloid cells (IBA1, green) around plaques (6E10, blue). b Cells expressing high levels of CD45 (magenta) around plaques (6E10, blue) were identified by immunohistochemistry and the percent CD45-positive area per plaque was quantified. c Proliferating (Ki67-positive, red) myeloid cells (IBA1-positive, green) were quantified across the entire cortex and hippocampus from one medial and one lateral section. Data from APPPS1–21; Trem2+/+ (n = 8), APPPS1–21;Trem2+/− (n = 8), and APPPS1–21;Trem2+/R47H (n = 10) mice are represented as mean ± SEM. *p < 0.05; ** p < 0.01; ***p < 0.001; ns - not significant. Representative images are from the cortexCC BY · PubMed Central
Fig. 3 Compact plaque number is specifically reduced in mice expressing the Trem2 R47H variant. Quantification of plaque burden was performed in APPPS1–21;Trem2+/+ (n = 15), APPPS1–21;Trem2+/− (n = 13), and APPPS1–21;Trem2+/R47H (n = 10) mice by (a) measuring 6E10 (red) and (b) Thioflavin S (green) positive plaque number and percent area across three cortical and one hippocampal region from 10 to 12 sagittal sections. Higher magnification of cortical (i) and hippocampal (ii) regions are shown. Data are presented as mean ± SEM. *p < 0.05; **p < 0.01
Fig. 3 Compact plaque number is specifically reduced in mice expressing the Trem2 R47H variant. Quantification of plaque burden was performed in APPPS1–21;Trem2+/+ (n = 15), APPPS1–21;Trem2+/− (n = 13), and APPPS1–21;Trem2+/R47H (n = 10) mice by (a) measuring 6E10 (red) and (b) Thioflavin S (green) positive plaque number and percent area across three cortical and one hippocampal region from 10 to 12 sagittal sections. Higher magnification of cortical (i) and hippocampal (ii) regions are shown. Data are presented as mean ± SEM. *p < 0.05; **p < 0.01CC BY · PubMed Central
Fig. 4 Neuritic dystrophy is increased in APPPS1–21 mice expressing the Trem2 R47H variant. a Immunohistochemistry was used to quantify dystrophic neurites in APPPS1–21;Trem2+/+ (n = 16), APPPS1–21;Trem2+/− (n = 15), and APPPS1–21;Trem2+/R47H (n = 10) mice by measuring (a) ubiquitin (magenta) and (b) N-terminal APP (n-APP, red) % area across the cortex and hippocampus. c Dystrophic neurite area (ubiquitin, magenta) normalized to plaque (6E10, blue) size was assessed in APPPS1–21;Trem2+/+ (n = 16), APPPS1–21;Trem2+/− (n = 15), and APPPS1–21;Trem2+/R47H (n = 10) mice. d The correlation between ubiquitin positive area and plaque size was plotted for one representative animal per Trem2 genotype and (e) r2 and (f) slope for the linear best fit lines were calculated. Data are presented as mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001
Fig. 4 Neuritic dystrophy is increased in APPPS1–21 mice expressing the Trem2 R47H variant. a Immunohistochemistry was used to quantify dystrophic neurites in APPPS1–21;Trem2+/+ (n = 16), APPPS1–21;Trem2+/− (n = 15), and APPPS1–21;Trem2+/R47H (n = 10) mice by measuring (a) ubiquitin (magenta) and (b) N-terminal APP (n-APP, red) % area across the cortex and hippocampus. c Dystrophic neurite area (ubiquitin, magenta) normalized to plaque (6E10, blue) size was assessed in APPPS1–21;Trem2+/+ (n = 16), APPPS1–21;Trem2+/− (n = 15), and APPPS1–21;Trem2+/R47H (n = 10) mice. d The correlation between ubiquitin positive area and plaque size was plotted for one representative animal per Trem2 genotype and (e) r2 and (f) slope for the linear best fit lines were calculated. Data are presented as mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

5 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 35 references

Cited by

See all 256

Metadata

Authors
Cheng-Hathaway, P. J., Reed-Geaghan, E. G., Jay, T. R., Casali, B. T., Bemiller, S. M., Puntambekar, S. S., von Saucken, V. E., Williams, R. Y., Karlo, J. C., Moutinho, M., Xu, G., Ransohoff, R. M., Lamb, B. T., & Landreth, G. E.
Affiliations
  • Indiana University Indianapolis (US)
  • Case Western Reserve University (US)
  • Indiana University School of Medicine (US)
  • Cleveland Clinic Research (US)
Corresponding author
Landreth, Gary E.
Venue
Molecular Neurodegeneration
Published
2018-06-01
Volume
13
Issue
1
Pages
29-29
ISSN
1750-1326 (ISSN-L)
OpenAlex
W2807252917
Cited by
252
References
35
Citations by year
2026: 27 · 2025: 24 · 2024: 24 · 2023: 45 · 2022: 21 · 2021: 29 · 2020: 48 · 2019: 22 · 2018: 11
FWCI
19.54
Type
journal article
Language
en
Open access
Licence
Locations
  • Molecular Neurodegeneration (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • IUScholarWorks (Indiana University) (submittedVersion, cc-by)
Funders
  • Alzheimer's Association
  • Case Western Reserve University (T32 NS077888, T32 GM725039)
  • National Institute on Aging (F30 AG055261, F31 AG048704, R01 AG051495, R01 AG050597)
  • Jane & Lee Seidman Fund
  • Chet & Jane Scholtz
  • Dave & Susan Roberts
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
TREM2, Alzheimer's disease, loss of function, myeloid cells, amyloid plaques, neuritic dystrophy, CD45, amyloid deposition, mouse model, genetic risk
MeSH terms
Alzheimer Disease, Animals, Brain, Membrane Glycoproteins, Phenotype, Receptors, Immunologic, Polymorphism, Single Nucleotide, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Trem2 R47H variant confers loss-of-function-like phenotypes in Alzheimer's disease. https://app.cochat.ai/papers/10.1186/s13024-018-0262-8
The paper
Cheng-Hathaway, P. J., Reed-Geaghan, E. G., Jay, T. R., Casali, B. T., Bemiller, S. M., Puntambekar, S. S., von Saucken, V. E., Williams, R. Y., Karlo, J. C., Moutinho, M., Xu, G., Ransohoff, R. M., Lamb, B. T., & Landreth, G. E. (2018). The Trem2 R47H variant confers loss-of-function-like phenotypes in Alzheimer's disease. Molecular Neurodegeneration. https://doi.org/10.1186/s13024-018-0262-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.